Condition
Ureteral Stent
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 3 (1)
Trial Status
Unknown2
Completed1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04829461Not ApplicableCompleted
Effectiveness of Ambu® aScope™ 4 Cysto With the aView™ 2 Advance for Flexible Cystoscopy
NCT06045962Not ApplicableActive Not RecruitingPrimary
Optimal Stent Duration After Ureteroscopy
NCT05738304Not ApplicableUnknown
Ureteral Stenting After Retrograde Intrarenal Surgery for Renal Stones
NCT04325880Phase 3UnknownPrimary
Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms
Showing all 4 trials